Neurocrine Biosciences — May 5, 2025 release

osciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance INGREZZA ® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITY TM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-’568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO , May 5, 2025 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance. “We delivered a record number of new patient starts for INGREZZA, which is especially impressive given the typically challenging first quarter. This strong performance gives us good momentum heading into the rest of the year. We are reaffirming 2025 INGREZZA net sales guidance of $2.5 to $2.6 billion,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “For CRENESSITY, we are encouraged by the initial launch and the positive receptivity among the congenital adrenal hyperplasia community. The combination of INGREZZA and CRENESSITY provides a solid foundation for near- and long-term revenue growth.” “With registrational programs for osavampator and NBI-’568 ongoing, an advancing early-to-